Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.49 |
| ▸ | GBA1 | P04062 | 2/20 | 0.46 |
| ▸ | UGCG | Q16739 | 2/20 | 0.46 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | OSBP | P22059 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14046807 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL14534344 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL17468531 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL345099 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL14538772 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL24141906 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL14554227 | 0.98 | POLA1 (0.51) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL22757123 | 0.95 | POLA1 (0.49) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL14878927 | 0.94 | POLA1 (0.46) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL16995494 | 0.94 | POLA1 (0.44) | POLA1CYP46A1GBA1UGCGGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230257740-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-20230053332-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210403917-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | US | disclosed |
| US-11149273-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210189393-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V | ALNYLAM PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3329924-B1 | DSRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| WO-2007111998-A2 | DSRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007056326-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF NAV1.8 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | ALNYLAM EUROPE AG (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | ALNYLAM EUROPE AG (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070042984-A1 | RNAi modulation of the Rho-A gene and uses thereof | BANK OF AMERICA, N.A. | 2007-02-22 | — | — | US | disclosed |
| US-20070044161-A1 | RNAi modulation of the Rho-A gene in research models | YALE UNIVERSITY | 2007-02-22 | — | — | US | disclosed |
| US-20070044161-A1 | RNAi modulation of the Rho-A gene in research models | YALE UNIVERSITY | 2007-02-22 | — | — | US | disclosed |
| US-20070042984-A1 | RNAi modulation of the Rho-A gene and uses thereof | BANK OF AMERICA, N.A. | 2007-02-22 | — | — | US | disclosed |
| WO-2007014077-A2 | RNAI MODULATION OF THE RHO-A GENE AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007014075-A2 | RNAI MODULATION OF THE RHO-A GENE IN RESEARCH MODELS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149273-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene | SAAL1, APOB, HNRNPAB | POLA1 1636/4885CYP46A1 167/4885GBA1 382/4885 |
| US-20210189393-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V | F5, F13B, F13A1 | POLA1 607/4885CYP46A1 1847/4885GBA1 807/4885 |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | POLA1 216/4885CYP46A1 1117/4885GBA1 248/4885 |
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | GNAQ, GNAI1, GNAI2 | POLA1 657/4885CYP46A1 3979/4885GBA1 499/4885 |
| US-20070044161-A1 | RNAi modulation of the Rho-A gene in research models | RHOA, RHOC, ARHGDIA | POLA1 2346/4885CYP46A1 1413/4885GBA1 1805/4885 |
| US-20210403917-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | PCSK9, PCSK7, RNASE1 | POLA1 326/4885CYP46A1 80/4885GBA1 244/4885 |
| US-20230053332-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | EGFR, ERBB3, ERBB2 | POLA1 923/4885CYP46A1 4216/4885GBA1 2503/4885 |
| US-20230257740-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | TTR, RNGTT, RNASE1 | POLA1 662/4885CYP46A1 847/4885GBA1 1021/4885 |
| US-20070042984-A1 | RNAi modulation of the Rho-A gene and uses thereof | RHOA, ARHGDIA, RHOC | POLA1 2746/4885CYP46A1 1564/4885GBA1 1605/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | POLA1 216/4885CYP46A1 1117/4885GBA1 248/4885 |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | TTR, CRYAA, SARNP | POLA1 917/4885CYP46A1 1935/4885GBA1 566/4885 |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | SCN8A, SCN7A, SCN5A | POLA1 1142/4885CYP46A1 4277/4885GBA1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.